|
Investor Relations
ApoImmune, Inc. is a biotechnology company developing novel immunotherapies, which are treatments based on the concept of regulating the immune system to fight disease. We are developing several innovative platform technologies for immunotherapies and vaccines that can support various research and development projects with significant commercial potential in the billions of dollars.
Currently, we are concentrating our clinical capabilities on cancer as we head toward our first Phase I clinical trial. Our other research programs include infectious disease, autoimmune disease with a focus on Type 1 diabetes, and cell/organ transplantation. To maximize the value of our proprietary technologies and products, ApoImmune seeks to collaborate or partner with research institutions and pharmaceutical and biotechnology companies.
To receive investor information, please contact:
Steven Downey
President and CEO
ApoImmune, Inc.
1044 East Chestnut Street
Louisville, KY 40204
T: 502-212-2493, ext. 303
sdowney[at]apoimmune.com
|
|
|
